Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer

Metabolic reprogramming in cancer targets glutamine metabolism as a key mechanism to provide energy, biosynthetic precursors and redox requirements to allow the massive proliferation of tumor cells. Glutamine is also a signaling molecule involved in essential pathways regulated by oncogenes and tumo...

Full description

Saved in:
Bibliographic Details
Published inSeminars in cell & developmental biology Vol. 98; pp. 34 - 43
Main Authors Matés, José M., Di Paola, Floriana J., Campos-Sandoval, José A., Mazurek, Sybille, Márquez, Javier
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.02.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Metabolic reprogramming in cancer targets glutamine metabolism as a key mechanism to provide energy, biosynthetic precursors and redox requirements to allow the massive proliferation of tumor cells. Glutamine is also a signaling molecule involved in essential pathways regulated by oncogenes and tumor suppressor factors. Glutaminase isoenzymes are critical proteins to control glutaminolysis, a key metabolic pathway for cell proliferation and survival that directs neoplasms’ fate. Adaptive glutamine metabolism can be altered by different metabolic therapies, including the use of specific allosteric inhibitors of glutaminase that can evoke synergistic effects for the therapy of cancer patients. We also review other clinical applications of in vivo assessment of glutaminolysis by metabolomic approaches, including diagnosis and monitoring of cancer.
ISSN:1084-9521
1096-3634
DOI:10.1016/j.semcdb.2019.05.012